{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009684","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.859320+00:00","generated_at":"2026-06-04T23:32:01.182383+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Imunon CEO Corinne Le Goff resigns; Executive Chairman Tardugno assumes interim leadership","bullets":["Dr. Corinne Le Goff resigned as President, CEO, and Board member, effective March 15, 2024, to pursue another opportunity.","Resignation was not due to any disagreement with the Company regarding operations, policies, or practices.","Executive Chairman Michael H. Tardugno (former CEO) will lead day-to-day operations until a successor is named.","Active CEO search is underway; development strategy and key program milestones remain unchanged.","Milestones: Phase 1 trial of IMNN-101 (COVID-19 booster) prep ongoing; OVATION 2 topline data for IMNN-001 expected summer 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009684","json":"https://secwatch.observer/filing/0001493152-24-009684.json","markdown":"https://secwatch.observer/filing/0001493152-24-009684.md","text":"https://secwatch.observer/filing/0001493152-24-009684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315224009684/0001493152-24-009684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315224009684/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:32:01.182383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cd329b63d","claim":"Corinne Le Goff resigned as President and Chief Executive Officer at Imunon, Inc..","evidence_excerpt":"On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the “Board”) of Imunon, Inc. (the “Company”) of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224009684/0001493152-24-009684-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}